Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Emerson (EMR) To Report Q3 Earnings: Beat In The Cards?

Published 08/01/2019, 10:18 PM

Emerson Electric Co. (NYSE:EMR) is set to release third-quarter fiscal 2019 (ended June 2019) results on Aug 6, before market open.

The company pulled off average positive earnings surprise of 2.80% over the last four quarters, beating estimates twice. Notably, in the last reported quarter, Emerson’s earnings of 84 cents per share came in line with the Zacks Consensus Estimate.

Year to date, the company’s shares have rallied 5.1% compared with the industry’s rise of 8%.



We expect it to score an earnings beat in the fiscal third quarter.

Why a Likely Positive Surprise?

Our proven model shows that Emerson has the right combination of the two key ingredients to beat earnings. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

This is the case here as you will see below:

Earnings ESP: Emerson has an Earnings ESP of +0.43%.

Emerson Electric Co. Price and EPS Surprise

Emerson Electric Co. price-eps-surprise | Emerson Electric Co. Quote

Zacks Rank: The company carries a Zacks Rank #3, which when combined with a positive ESP, makes us reasonably confident of an earnings beat.

Conversely, we caution against stocks with a Zacks Ranks #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is witnessing negative estimate revisions.

Factors Likely to Drive Better-Than-Expected Q3 Results

Emerson expects strength in brownfield, greenfield as well as maintenance, repair and operations projects to bolster revenues of its Automation Solutions segment in the to-be reported quarter. Also, favorable residential and commercial air-conditioning markets in North America, and strength in global professional tools markets, will drive the top line of the company’s Commercial & Residential Solutions segment.

The company’s acquisitions are also anticipated to be conducive to its revenues in the to-be reported quarter. The company used $243 million for making acquisitions (net of cash acquired) in the first half of fiscal 2019 (ended March 2019). As noted, it added six buyout assets to the Automation Solutions segment, including the Intelligent Platforms business of General Electric Company (NYSE:GE) in February 2019. We expect the acquisitions to drive sales in the fiscal third quarter as well.

Moreover, Emerson believes that benefits from its cost-reduction efforts and greater operational efficacy will boost profitability.

Amid this backdrop, the Zacks Consensus Estimate for revenues from the Automation Solutions segment in third-quarter fiscal 2019 is currently pegged at $3,108 million, higher than $2,870 million reported in the year-ago quarter. Revenues from Commercial & Residential Solutions segment are expected to be $1,726 million, indicating a rise from $1,592 million reported a year ago.

Despite these positives, escalating cost of sales and expenses are a major concern for Emerson. As a matter of fact, increase in costs might dent profits and lead to margin contraction.

Other Key Picks

Here are two other companies from the Zacks Industrial Products sector you may want to consider as our model shows that these have the right combination of elements to beat estimates this earnings season:

Axon Enterprise, Inc. (NASDAQ:AAXN) has an Earnings ESP of +10.21% and a Zacks Rank of 1.You can see the complete list of today’s Zacks #1 Rank stocks here.

Sealed Air Corporation (NYSE:SEE) has an Earnings ESP of +1.34% and a Zacks Rank of 2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Sealed Air Corporation (SEE): Free Stock Analysis Report

General Electric Company (GE): Free Stock Analysis Report

Emerson Electric Co. (EMR): Free Stock Analysis Report

Axon Enterprise, Inc (AAXN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Gracias Julia por tus análisis
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.